Newsletter | April 24, 2026

04.24.26 -- Europe Remains Resilient Through Uncertainty

INDUSTRY INSIGHTS

What To Look For In A Pharma Contract Packaging Partner

Teams face rising pressure around compliance, complexity, and speed. These five essential qualities help identify packaging partners who can support production, reduce risk, and align with your needs.

Converting From A Spray-Dried Dispersion In <5 Months

A development team quickly turned a low‑bioavailability, high‑burden formulation into a streamlined, clinically improved version, boosting exposure, simplifying manufacturing, and accelerating progress.

Compressing Analytical Timelines Without Cutting Corners

Efficient analytical development speeds decisions and improves risk visibility. Using QbD, digital tools, and strong communication helps teams accelerate timelines while maintaining rigor.

FEATURED EDITORIAL

Europe Remains Resilient Through Uncertainty

Chief Editor Louis Garguilo wants readers to focus again on Europe as it remains so vital to development and manufacturing outsourcing. Europe’s CDMOs didn’t wait for some form of political or trade détente; they leveraged their tradition and reputation for reliability. He thinks 2026 may be remembered as the year Europe’s industry redefined resilience.

How To Implement Post-Approval Changes On A Global Level

To prepare for inevitable process changes after market authorization, this overview provides critical planning advice for assessing risk and minimizing delays.

INDUSTRY INSIGHTS CONTINUED

Innovative Softgel Technologies To Deliver Poorly Soluble Molecules

Learn how to expedite the development pathway for early phase compounds and how lipid based formulations provide an innovative approach to enhance bioavailability for challenging molecules.

Precision Powder-In-Capsule Micro-Dosing Accelerates Drug Development

Precision powder microdosing makes it possible to quickly get formulations to the clinic, saving time, money, and use of limited APIs.

Selecting A CDMO For Custom Activated PEGs

Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.

SOLUTIONS

Protein Degraders: From Discovery To Development

Improving Die Table Performance Through Advanced Surface Technology

From Development To Commercial Supply—Delivered

Connect With Outsourced Pharma: